Rapid evaluation of risk of white particulate matter in blood components by a statewide survey of transfusion reactions

Transfusion

Volumn 44, Issue 7, 2004, Pages 967-972

  Iwamoto, M ^b   Curns, A T ^b   Blake, P A ^b   Jernigan, D B ^b   Holman, R C ^b   Lance Parker, S E ^b   Chamberland, M E ^b   Kuehnert, Matthew J ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGIC REACTION; ARTICLE; BACTERIUM CONTAMINATION; BLOOD COMPONENT; BLOOD TRANSFUSION REACTION; CONTROLLED STUDY; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; EVALUATION; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; PARTICULATE MATTER; PLASMA TRANSFUSION; QUESTIONNAIRE; RISK ASSESSMENT; THROMBOCYTE TRANSFUSION; WHITE PARTICULATE MATTER;

BLOOD SPECIMEN COLLECTION; BLOOD TRANSFUSION; HUMANS; RETROSPECTIVE STUDIES; RISK; SAFETY;

EID: 3042636950     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2004.03319.x     Document Type: Article

References (23)

1. Solis RT, Goldfinger D, Gibbs MB, Zeller JA. Physical characteristics of microaggregates in stored blood. Transfusion 1974;14:538-50.
2. McNamara JJ, Anderson BS, Hayashi T. Stored blood platelets and microaggregate formation. Surg Gynec Obstet 1978;147:507-12.
3. Linko K. Conditions on the removal of microaggregates from stored blood by centrifugation and filtration through a standard 170-μm transfusion filter. Transfusion 1983;23:310-2.
4. Andreu G, Morel P, Forestier F, et al. Hemovigilance network in France: organization and analysis of immediate transfusion incident reports from 1994 to 1988. Transfusion 2002;42:1356-64.
5. FDA. Information alert on particulate matter in blood bags. Rockville, MD: Center for Biologics Evaluation and Research, February 7, 2003. Accessed March 12, 2004, at http://www.fda.gov/cber/infosheets/alertprtbld.htm.
6. FDA. Update on FDA's continuing investigation of particulate matter in blood show normal blood components and no evidence for an increase in adverse events. FDA News, February 27, 2003. Accessed March 12, 2004, at http://www.fda.gov/bbs/topics/NEWS/2003/NEW00874.html.
7. FDA. Update on particulate matter in blood bags. Rockville, MD: Center for Biologics Evaluation and Research, October 31, 2003. Accessed March 12, 2004, at http://www.fda.gov/cber/infosheets/bldpartic.htm.
8. Vamekas EC, Pineda AA. Allergic and anaphylactic reactions. In: Popovsky MA, ed. Transfusion reactions, 2nd ed. Bethesda, MD: AABB Press, 2001:83-127.
9. Domen RD, Hoeltge GA. Allergic transfusion reactions. Arch Pathol Lab Med 2003;127:316-20.
10. Sazama K, DeChristopher PJ, Dodd R, et al. Practice parameter for the recognition, management, and prevention of adverse consequences of blood transfusion. Arch Pathol Lab Med 2000;124:61-70.
11. Menitove JE, McElligott MC, Aster RH. Febrile transfusion reaction: what blood component should be given next? Vox Sang 1982;42:318-21.
12. Linden JV, Wagner K, Voytovich AE, Sheehan J. Transfusion errors in New York State: an analysis of 10 years' experience. Transfusion 2000;40:1207-13.
13. Kopko PM, Marshall CS, MacKenzie MR, et al. Transfusion-related acute lung injury: report of a clinical look-back investigation. JAMA 2002;287:1968-71.
14. Hillyer CD, Silberstein LE, Ness PM, Anderson KC, eds. Blood banking and transfusion medicine: basic principles and practice. Philadelphia: Churchill Livingston, 2003.
15. Faber JC. Haemovigilance around the world. Vox Sang 2002;83(Suppl 1):71-6.
16. Debeir J, Noel L, Aullen JL, et al. The French hemovigilance system. Vox Sang 1999;77:77-81.
17. Williamson LM. Systems contributing to the assurance of transfusion safety in the United Kingdom. Vox Sang 1999;77:82-7.
18. FDA. Notification process for transfusion related fatalities and donation related deaths. Rockville, MD: FDA, Center for Biologics Evaluation and Research, May 2002. Accessed March 12, 2004, at http://www.fda.gov/cber/ transfusion .htm.
19. FDA. MedWatch: the FDA safety information and adverse event reporting program. Rockville, MD: FDA, Center for Biologics Evaluation and Research, July 2003. Accessed March 12, 2004 at http://www.fda.gov/medwatch.
20. Busch M, Chamberland ME, Epstein J, et al. Oversight and monitoring of blood safety in the United States. Vox Sang 1999;77:67-76.
21. Kuehnert MJ, Roth VR, Haley NR, et al. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion 2001;41:1493-9.
22. Pealer LN, Marfin AA, Petersen LR, et al. Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med 2003;349:1236-45.
23. Iwamoto M, Jernigan DB, Gausch A, et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med 2003;348:2196-203.